CSPC Pharmaceuticals (HKG: 1093) shares are up 11.5% in Hong Kong today. The cause here seems to be the approval to start testing of a new cancer treatment. At which point we should note something ...

Detailed price information for Cspc Pharm Group Ltd Ord (CHJTF) from The Globe and Mail including charting and trades.

Detailed price information for Cspc Pharm Group Ltd Ord (CHJTF) from The Globe and Mail including charting and trades.

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...

In business as in medicine, a remedy can take time to kick in. This is the challenge for Chinese drug giant CSPC Pharmaceutical Group Ltd. (1093.HK), which is trying to transform itself from being a ...

DelveInsight's Castration-sensitive Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, CSPC emerging drugs, market share of individual ...

CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration for their Tedizolid Phosphate Tablets. This novel antibiotic is designed to treat acute bacterial ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: Moderna's COVID-19 vaccine at the McKesson distribution center in Olive Branch, Mississippi FILE PHOTO: Moderna's ...

CSPC operates in a fast-growing and rapidly changing environment. Like most healthcare sectors in China, drug manufacturing has grown faster than GDP, and is projected to continue this trend over the ...

Narrow-moat CSPC’s 01093 interim results fell short of expectations. Revenue for the six months grew 3% year on year whereas operating profit, calculated with cost of sales and expenses for sales, ...

SHANGHAI, Jan 30 (Reuters) - AstraZeneca will license experimental drugs for obesity and weight-related conditions from CSPC Pharmaceutical Group and collaborate on other projects, paying $1.2 billion ...

In a study of oligometastatic castration-sensitive prostate cancer, metastasis-directed therapy (MDT) with concurrent ADT vs MDT alone was significantly associated with a greater 5-year rate of ...